X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Innovation and Responsibility for Patients Well-Being: Digitalization at the Family Business Vetter

Content Team by Content Team
14th September 2021
in Drug Development, IPR Data Management, Press Statements
Innovation and Responsibility for Patients Well-Being: Digitalization at the Family Business Vetter

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The healthcare industry is rapidly changing. People, machines, and information are becoming increasingly interconnected. Due to the COVID-19 pandemic, innovations at the interface between pharmaceutical products, services, and digital datahad to be accelerated. Vetter, a leading contract development and manufacturing organization (CDMO) is undergoing change too, testing future technology and implementing new digital systems. Our mission remains the same: To sustainably improve the patients’ quality of life with the drugs we produce.

Although the digital transformation is behind many of the advances Vetter has made and is deeply rooted in our company strategy, it is not self-serving. As a leading company in the aseptic filling and packagingof syringes, cartridges, and vials, we have a great responsibility. Put another way, our jobs are about people’s lives. Digitalization becomes important for us when it significantly and justifiably further improves quality and processesfor our customers and especially the millions of patients who rely on them for their medication. Vetter produces drugs that are crucial for many people’s lives worldwide. Among them are therapies for the treatment of cancer, rheumatism, or multiple sclerosis, as well as medications for rare diseases.

Reliable, efficient, and safe processes are the very essence of our industry. The regulatory specifications in the pharmaceutical environment are very restrictive,and for good reason. However, this also means to leverage digitalization we must overcome a higher complexity.

The future is now
Digitalization at Vetter is already being lived on an everyday basis. Our company strategy,Vetter NExT 2029, is being developed with staff members in virtual workshops. Many of the collected ideas and challenges deal with our digital roadmap.

The digital change at Vetter has many features. Within the scope of digitalizing central key processes, the future factory processes are a part of our focus. We are therefore dealing with topics such as predictive maintenance, visual remote services, or intelligent worker assistance systems to significantly reduce standstill and troubleshooting times.

Artificial intelligence (AI) has already been implemented at our company with the successful usage of machine learning systems. We are working on projects such as generating text from data – the so-called natural language generation, up to complex forecasting projects in the context of controlling. Moreover, we will rely on robotic process automation for recurring and clearly-defined tasks in the future.

To strive for innovation on a continuous basis is what we consider an integral part of our responsibility. We develop some of these digital infrastructures completely in-house and are, thus, setting up important competencies that are becoming increasingly significant for ourfuture.

People are always at the center
The implementation of digital processes concerns the essential core processes of Vetter. Within the scope of our wide-ranging digitalization strategy, we focus on, among other things, projects in the topic areas production, quality, and the supply chain. But digitalization is also advancing in the administrative areas with a wide variety of projects.

While digitalization is increasing, the activities and procedures at work change as well. How can we manage to undergo this change in a sustainable and successful way? This can only be done via people who feel confident and comfortable with applying new technologies. Our staff members have helped shape Vetter for over 70 years. Today, they number around 5,500 on three continents and are the most important success factor of our digital journey.

Kai Vogt, Senior Vice President Corporate Development/Legal/Corporate Compliance/IT

Since October 2016, Kai Vogt has managed Corporate Development, Legal/Corporate Compliance as well as IT at Vetter Pharma-Fertigung GmbH & Co. KG. After completing his commercial training and business studies, he took over operational and strategic responsibility in the industrial sector and consulting. Prior to his position as Senior Manager at Vetter, he was, among others, responsible for the international corporate development at centrotherm and Bilfinger Industrial Services. Together with his team and the respective departments, he drives the implementation of the company strategy and, among others, focuses on the digitalization of the core business at Vetter.

 

About Vetter

Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. Currently employing 5,500 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

Previous Post

Takeda to Manufacture and Provide 150 Million Doses of Novavax COVID-19 Vaccine Candidate to the Government of Japan

Next Post

BMG Pharma and HTL sign a development agreement to manufacture BMG's new biopolymer based on the Hyaluromimethic Technology

Related Posts

Pharma Advancement Banner
Press Statements

Welcome to the Inaugural Operationalize: Expanded Access Programs Summit West

27th June 2025
Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Next in Pharma 2025 Innovations
Articles

Next in Pharma 2025: Innovations Shaping the Future

28th May 2025
Next Post
BMG Pharma and HTL sign a development agreement to manufacture BMG's new biopolymer based on the Hyaluromimethic Technology

BMG Pharma and HTL sign a development agreement to manufacture BMG's new biopolymer based on the Hyaluromimethic Technology

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In